医学
硼替佐米
内科学
淀粉样变性
淀粉样变性
心脏淀粉样变性
多发性骨髓瘤
重症监护医学
数据库
免疫球蛋白轻链
计算机科学
抗体
免疫学
作者
Angela Dispenzieri,Jeffrey A. Zonder,James E. Hoffman,Sandra W. Wong,Michaela Liedtke,Rafat Abonour,Anita D’Souza,Charlene Lee,Sarah Côté,Ravi Potluri,Eric M. Ammann,NamPhuong Tran,Annette Lam,Sandhya Nair
出处
期刊:Amyloid
[Informa]
日期:2022-10-25
卷期号:30 (2): 161-168
被引量:1
标识
DOI:10.1080/13506129.2022.2137400
摘要
Background This study characterised real-world treatment patterns, clinical outcomes, and cost-of-illness in patients with light-chain (AL) amyloidosis.Methods Data were extracted from the US-based Optum® EHR and Clinformatics® Data Mart (claims) databases (2008–2019) for patients newly diagnosed with AL amyloidosis and who initiated anti-plasma cell therapies. Healthcare resource utilisation (HCRU) and related costs were compared across lines of therapy (LOT). Incidences of cardiac and renal failure were evaluated using the Kaplan-Meier method.Results About 1347 patients (EHR, n = 776; claims, n = 571) were included. Median age was 68 years; 56.8% were male. At initial diagnosis, 33.1% and 15.1% of patients had cardiac and renal failure, respectively. Most patients received bortezomib-containing treatment in LOT1 (69%); bortezomib-cyclophosphamide-dexamethasone was most common (26%). HCRU was similar across LOTs. Mean per-patient-per-month and per-patient-per-LOT costs were $19,343 and $105,944 for LOT1, $19,183 and $95,793 for LOT2, and $16,611 and $128,446 for LOT3, respectively. Costs were primarily driven by anti-plasma cell therapies, outpatient visits, and hospitalisations. The 5-year cardiac and renal failure rates following initial diagnosis were 64.5% and 39.0%, respectively.Conclusion AL amyloidosis is associated with substantial costs and suboptimal outcomes, highlighting the need for new therapeutic approaches to prevent organ deterioration, and reduce disease burden.
科研通智能强力驱动
Strongly Powered by AbleSci AI